Fate (FATE) Announces Encouraging Data On Immunotherapies
Zacks Investment Research | Dec 09, 2019 09:48PM ET
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) surged 41.3% after the company came out with positive data on experimental cancer candidates.
The company announced initial clinical data on its candidates — FT516 and FT500. Both are off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell product candidates.
FT516 is being investigated in an open-label, multi-dose phase I clinical study as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-directed monoclonal antibodies for the treatment of advanced B-cell lymphoma. The initial findings show the absence of morphologic evidence of leukemia (at day 42) along with complete neutrophil recovery in the first patient treated with FT516 monotherapy for AML following the first dosing cycle.
FT500 is the first iPSC-derived cell product candidate from the iPSC product platform. The study on FT500 is an open-label, multi-dose phase I trial being conducted for the treatment of advanced solid tumors. The dose-escalation stage of the study is designed to assess the safety and tolerability of three once-weekly doses of FT500, without IL-2 cytokine support, as a monotherapy and in combination with one of the three FDA-approved immune checkpoint inhibitor (ICI) therapies in patients who have failed prior ICI therapy.
Initial data showed that there were no dose-limiting toxicities or FT500-related serious adverse events reported in the first 12 patients treated with the candidate for advanced solid tumors.
The safety, tolerability and immunogenicity profile from the phase I dose-escalation stage of FT500 was favorable and provided evidence that multiple doses of iPSC-derived NK cells can be delivered off the shelf and administered without patient matching.
Fate’s stock has soared 50.6% in the year so far compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.